Long-term, higher-dose continuous subcutaneous apomorphine infusion (CSAI; Onapgo; Supernus Pharmaceuticals) appears to be safe and tolerable for patients with advanced Parkinson disease (PD), according to data from a real-world European-based…
Real-World EU Data Suggest Safety of High-Dose Apomorphine Infusion in Parkinson Disease | NeurologyLive
